Torsten Dreier

Torsten is the CDO at Agomab and brings an extensive expertise in developing antibodies and antibody-based drugs with more than 20 years in the pharmaceutical industry. He has a successful track record of progressing 10 antibody products from preclinical research to clinical development, including two (Blincyto and Cablivi) that obtained marketing authorization. Prior to joining Agomab, Torsten was the Co-Founder and Chief Development Officer at argenx, overseeing various aspects of drug development. Between 2003 and 2008, he was at Ablynx, where he was responsible for pharmacology, toxicology, bioanalytics and CMC as well as early clinical development. Torsten holds a PhD in Biochemistry from the University of Tübingen, Germany.